IDEXX LABORATORIES INC /DE Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
IDEXX LABORATORIES INC /DE (IDXX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $185.90 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-20
- IDEXX LABORATORIES INC /DE share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $185.90M, a 116.92% increase from fiscal 2024.
- IDEXX LABORATORIES INC /DE share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $85.70M, a 13.51% increase from fiscal 2023.
- IDEXX LABORATORIES INC /DE share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $75.50M, a 38.28% increase from fiscal 2022.
- IDEXX LABORATORIES INC /DE share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $54.60M, a 63.08% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2025-12-31 | $185.90M 10-K · filed 2026-02-20 |
| 2024-12-31 | $85.70M 10-K · filed 2026-02-20 |
| 2023-12-31 | $75.50M 10-K · filed 2026-02-20 |
| 2022-12-31 | $54.60M 10-K · filed 2025-02-21 |
| 2021-12-31 | $147.90M 10-K · filed 2024-02-22 |
| 2020-12-31 | $163.00M 10-K · filed 2023-02-16 |
| 2019-12-31 | $83.70M 10-K · filed 2022-02-16 |
| 2018-12-31 | $87.10M 10-K · filed 2021-02-12 |
| 2017-12-31 | $78.30M 10-K · filed 2020-02-14 |
| 2016-12-31 | $51.00M 10-K · filed 2019-02-15 |
| 2015-12-31 | $35.10M 10-K · filed 2018-02-16 |
| 2014-12-31 | $51.20M 10-K · filed 2017-02-17 |
| 2013-12-31 | $49.00M 10-K · filed 2016-02-17 |
| 2012-12-31 | $45.80M 10-K · filed 2015-02-17 |
| 2011-12-31 | $54.70M 10-K · filed 2014-02-18 |
| 2010-12-31 | $60.10M 10-K · filed 2013-02-19 |
| 2009-12-31 | $22.10M 10-K · filed 2012-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |